Avista Capital Partners Mergers and Acquisitions Summary

Private Equity Profile

In the last 3 years, Avista Capital Partners has acquired 6 companies. It has also invested in 2 others.

Avista Capital Partners’ most common sectors for investment are life science (27%) and medical products (16%). The Firm’s most common investment types include buyout (lbo, mbo, mbi) (35%) and secondary buyout (27%). In total, Avista Capital Partners has invested in 15 US states and 7 different countries. Its largest (disclosed) acquisition occurred in 2008 when it acquired ConvaTec for $4.1B.

In the last 3 years, Avista Capital Partners has exited 5 companies. The Firm’s most common exit type is trade sale (49%). Avista Capital Partners’ largest (disclosed) exit occurred in 2011 when it sold Nycomed Pharma AG for $10.8B.

Join Mergr to view Avista Capital Partners’ full profile and discover more mega-sized private equity firms just like it.

M&A Summary

  • M&A Total Activity73
    • M&A Buy Activity46
    • M&A Sell Activity27
  • Total Sectors Invested 18
  • Total Countries Invested 7
  • M&A Buy/Sell Connections 29
  • M&A Advisors 12

Avista Capital Partners

65 East 55th Street,18th Floor,
New York, New York 10022
United States
(212) 593-6900
www.avistacap.com
info@avistacap.com

Avista Capital Partners is a private investment firm formed by a group of professionals with roots from DLJ Merchant Banking Partners. Avista makes controlling and minority investments in US based energy, healthcare, and media companies with revenues greater than $25 million. Typical transactions include leverage buyouts, build-ups, and growth capital financings. Avista Capital was formed in 2005 and is based in New York City with an additional office in Houston, Texas.


Investment Criteria

Sectors of Interest: Automotive, Business Services, Communications, Distribution, Energy Services and Equipment, Engineering, Environmental, Financial Services, Healthcare Services, Life Science, Manufacturing, Marketing, Media, Medical Products, Oil/Gas Exploration, Publishing, Renewable Energy, Utilities

Target Transaction Types: Buyout (LBO, MBO, MBI), Consolidation, Growth Capital, Recapitalization

Geographic Preferences: East US, Midwest US, South US, West US

Transaction Criteria Min Max
Target Revenue 25 -
Target EBITDA - -
Investment Size 50 300
Enterprise Value - -
values in millions of USD

M&A Summary

Buy vs Sell

Year ≤ '16 '17 '18 '19 '20 '21 T
Buy (2.2/yr) # 35 3 4 1 2 1 46
vol $6.9B $344M $7.3B
Sell (1.2/yr) # 21 1 4 1 - - 27
vol $17.4B $525M $402M $18.3B
  73

Most Recent M&A

Company Date Value Type
eMolecules, Inc. 2021-03-25 - Growth Capital
San Diego, California · www.emolecules.com
Solmetex LLC 2020-12-17 - Secondary Buyout
Marlborough, Massachusetts · www.solmetex.com
Vision Healthcare N.V. 2020-06-01 344M EUR Divestiture
Kortrijk, Belgium · www.visionhealthcare.eu
GCM Holding Corp. 2019-09-03 - Secondary Buyout
Union, California · www.gogcm.com
Trimb Healthcare AB 2019-06-24 402M SEK Add-on Acquisition
Stockholm, Sweden · www.trimb.se
Organogenesis, Inc. 2018-12-10 - Secondary Buyout
Canton, Massachusetts · www.organogenesis.com
G&W Dermatology 2018-11-06 - Divestiture
, New Jersey
Telular Corp. 2018-11-01 525M USD Add-on Acquisition
Chicago, Illinois · www.telular.com
Osmotica Pharmaceuticals Plc 2018-10-22 - PIPE
Bridgewater, New Jersey · www.osmotica.com
Sidewinder Drilling, Inc. 2018-07-19 - Trade Sale
Houston, Texas · www.sidewinderdrilling.com
View All >>

Portfolio M&A

Company Acquired Add-On/Sale Date #
Acino International AG 2013-10-02 IlmixGroup - Select Portfolio of Prescription Pharmaceutical Products and Food Supplements 2021-04-01 5
Zurich, Czech Republic · www.acino.swiss Saint Petersburg, Russia
Vision Healthcare N.V. 2020-06-01 NaturaMed Pharma AS 2020-12-21 2
Kortrijk, Belgium · www.visionhealthcare.eu Drammen, Netherlands · www.naturamed-pharma.no
Arcadia Consumer Healthcare, Inc. 2018-05-02 Chattem, Inc. 2020-03-20 3
Bridgewater, New Jersey · www.arcadiach.com Chattanooga, Tennessee · www.kaopectate.com
Acino International AG 2013-10-02 Takeda Pharmaceutical Co.,Ltd. - Primary Care Portfolio 2019-10-15 4
Zurich, Czech Republic · www.acino.swiss Osaka, Japan
Arcadia Consumer Healthcare, Inc. 2018-05-02 Nizoral 2018-06-25 2
Bridgewater, New Jersey · www.arcadiach.com Fort Washington, Pennsylvania · www.nizoral.com
Acino International AG 2013-10-02 Litha Healthcare Group Ltd. 2017-02-28 3
Zurich, Czech Republic · www.acino.swiss Midrand, South Africa · www.lithahealthcare.co.za
Acino International AG 2013-10-02 Acino Holding AG - Transdermal Drug Delivery Systems Business 2016-11-30 1
Zurich, Czech Republic · www.acino.swiss Aesch, Czech Republic
Acino International AG 2013-10-02 Norgine - Middle East & North Africa Operations & Product Right 2016-06-28 2
Zurich, Czech Republic · www.acino.swiss , Netherlands

M&A by Sector

Sector Current # Value All-time # Value
Life Science 7 (47%) 757M (100%) 12 (26%) 1.4B (19%)
Medical Products 1 (7%) - 7 (15%) 4.6B (64%)
Oil/Gas Exploration 2 (13%) - 5 (11%) 405M (6%)
Healthcare Services 1 (7%) - 4 (9%) 635M (9%)
Energy Services and Equipment - - 3 (7%) -
Information Technology - - 2 (4%) 253M (3%)
Communications - - 2 (4%) -
Apparel/Textiles - - 1 (2%) -
Automotive - - 1 (2%) -
Business Services - - 1 (2%) -
Consumer Products 1 (7%) - 1 (2%) -
Distribution - - 1 (2%) -
Environmental - - 1 (2%) -
Machinery 1 (7%) - 1 (2%) -
Manufacturing - - 1 (2%) -
Marketing 1 (7%) - 1 (2%) -
Publishing - - 1 (2%) -
Software 1 (7%) - 1 (2%) -
Total 15 $757M 46 $7.3B

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 12 (80%) - 39 (85%) 6.5B (90%)
  Texas 1 (7%) - 8 (17%) 405M (6%)
  New Jersey 3 (20%) - 6 (13%) 4.1B (56%)
  California 2 (13%) - 5 (11%) -
  Maryland 2 (13%) - 4 (9%) 210M (3%)
  Massachusetts 2 (13%) - 3 (7%) 525M (7%)
  Minnesota 1 (7%) - 2 (4%) -
  Pennsylvania - - 2 (4%) -
  New York - - 2 (4%) -
  Ohio 1 (7%) - 1 (2%) -
  North Carolina - - 1 (2%) 600M (8%)
  Illinois - - 1 (2%) 253M (3%)
  District of Columbia - - 1 (2%) -
  Connecticut - - 1 (2%) -
  Colorado - - 1 (2%) -
United Kingdom 1 (7%) - 2 (4%) -
Czech Republic 1 (7%) 414M (55%) 1 (2%) 414M (6%)
Belgium 1 (7%) 344M (45%) 1 (2%) 344M (5%)
Denmark - - 1 (2%) -
Sweden - - 1 (2%) -
Switzerland - - 1 (2%) -
Domestic 12 (80%) - 39 (85%) 6.5B (90%)
Cross-border 3 (20%) 757M (100%) 7 (15%) 757M (10%)
Total 15 $757M 46 $7.3B

Acquisitions by Deal Type

Type Current # Value All-time # Value
Buyout (LBO, MBO, MBI) 2 (13%) - 16 (35%) 350M (5%)
Secondary Buyout 5 (33%) - 12 (26%) 600M (8%)
Divestiture 4 (27%) 344M (45%) 8 (17%) 5.6B (77%)
Growth Capital 2 (13%) - 5 (11%) -
Going Private 1 (7%) 414M (55%) 2 (4%) 667M (9%)
PIPE 1 (7%) - 2 (4%) -
Stake Purchase - - 1 (2%) 55M (1%)
Total 15 $757M 46 $7.3B

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 12 (44%) 18.3B (100%)
IPO 5 (19%) -
Secondary Sale 4 (15%) -
Trade Sale 2 (7%) -
Bankruptcy 1 (4%) -
Merger 1 (4%) -
Sold to Management 1 (4%) -
Unknown 1 (4%) -
Total 27 $18.3B

Top M&A Advisors

Financial Deals
Credit Suisse Investment Banking
 2
J.P. Morgan Securities LLC
 1
Rothschild Global Advisory
 1
Legal Deals
Ropes & Gray LLP
 6
Kirkland & Ellis LLP
 5
Weil Gotshal & Manges LLP
 4

Deal Values

buy # Total
> $1B 1 $4.1B
$100M to $1B 8 $3.1B
< $100M 1 $55M
TOTAL $7.3B
Largest ConvaTec, Inc.
$4.1B (2008-08-02)
sell # Total
> $1B 4 $15.9B
$100M to $1B 6 $2.4B
TOTAL $18.3B
Largest Nycomed Pharma AG
$10.8B (2011-05-19)

M&A Connections

Deals
Acquired from
Investor(s)
26%
12 (26%)
Strategic(s)
13%
6 (13%)
Exited to
Investor(s)
15%
4 (15%)
Strategic(s)
52%
14 (52%)

Investor Summary

Size

Mega

PE Assets

6.0B USD

Established

2005

Specialist/Generalist

Specialist

Leadership

David Burgstahler

Co-founder & Managing Partner, Co-CEO

Thompson Dean

Co-Founder, Co-Managing Partner & Co-CEO

Amanda Heravi

Founding Member & Head of Investor Relations

John Cafasso

CFO

Robert Girardi

Partner

 Subscribe to unlock this and 165,499
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.2K Private Equity Firms
  • 154K M&A Transactions
  • 161K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.3K M&A Advisors
    (Investment Banks and Law Firms)
  • 51K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal